Complete Filing Data
Semnur Pharmaceuticals, Inc. reported Stockholders Equity of -$20.75 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Semnur Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income Loss | -$160.4M | -$4.7M | $632.5K | -$419.4K |
| Operating Income Loss | -$160.4M | -$4.7M | -$3.2M | |
| Interest Expense Nonoperating | $96.2K | $36.9K | ||
| Research And Development Expense | $2.5M | $1.7M | ||
| Operating Expenses | $160.4M | $4.7M | ||
| General And Administrative Expense | $157.9M | $3.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$152.6M | -$999.0K | -$665.0K | -$167.3K | -$1.3M | -$1.1M | -$1.5M | $632.5K | $630.6K | $457.7K | -$1.0M | $307.5K | -$30.8K | -$11.3K |
| Operating Income Loss | -$152.6M | -$374.9K | -$246.6K | -$1.3M | -$168.2K | -$368.3K | -$505.9K | -$563.7K | ||||||
| Interest Expense Nonoperating | $28.3K | $27.0K | $25.2K | $23.1K | $21.3K | $14.7K | ||||||||
| Research And Development Expense | $1.1M | $233.0K | ||||||||||||
| Operating Expenses | $152.6M | $1.3M | ||||||||||||
| General And Administrative Expense | $151.5M | $1.1M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | -$20.8M | -$42.8M | -$38.1M | -$3.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $20.0K | $12.0K | $12.0K | $819.7K |
| Retained Earnings Accumulated Deficit | -$275.8M | -$115.4M | -$8.3M | -$3.3M |
| Liabilities Current | $10.2M | $35.0K | $5.6M | $1.3M |
| Liabilities And Stockholders Equity | $1.3M | $6.7M | $50.7M | $86.3M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $8.0K | $0.00 | -$615.3K | $819.7K |
| Assets Current | $596.0K | $6.0M | $209.4K | $907.8K |
| Assets | $1.3M | $6.7M | $50.7M | $86.3M |
| Liabilities | $22.1M | $49.5M | $8.5M | $4.2M |
| Assets Held In Trust Noncurrent | $50.5M | $85.4M | ||
| Cash | $20.0K | $12.0K | $819.7K | |
| Temporary Equity Carrying Amount Attributable To Parent | $50.5M | |||
| Deferred Underwriter Compensation Non Current | $2.9M | $2.9M | ||
| Temporary Equity Accretion To Redemption Value Adjustment | $2.0M | $5.6M | $16.1M | |
| Accounts Payable And Other Accrued Liabilities Current | $3.7M | $1.3M | ||
| Other Notes Payable Current | $975.0K | |||
| Other Accrued Liabilities Current | $18.9K | |||
| Preferred Stock Value | $1.0K | $0.00 | ||
| Repayments Of Related Party Debt | $240.0K | |||
| Cash And Cash Equivalents At Carrying Value | $20.0K | $12.0K | $819.7K | |
| Common Stock Value | $23.0K | $20.0K | ||
| Subsequent Measurement Of Common Stock Subject To Possible Redemption Value | $1.2M | |||
| Property Plant And Equipment Net | $750.0K | $689.0K | ||
| Other Assets Current | $0.00 | $6.0M | ||
| Accrued Liabilities Current | $739.0K | $35.0K | ||
| Temporary Equity Accretion To Redemption Value | $16.1M | |||
| Deferred Offering Cost Settled Through Related Party | $203.7K | |||
| Subsequent Measurement Of Common Stock Subject To Possible Redemption | $5.6M | $495.3K | ||
| Accounts Payable And Accrued Liabilities Current | ||||
| Notes Payable Current | $3.5M | $0.00 | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $819.7K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$14.6M | -$44.4M | -$43.4M | -$42.0M | -$40.7M | -$39.6M | -$7.9M | -$6.6M | -$5.2M | -$1.9M | -$1.7M | $13.7K | $0.00 | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $85.0K | $126.00 | $2.7K | $13.0K | $1.5K | $1.0K | $13.5K | $9.1K | $579.4K | $985.6K | $1.1M | $16.6K | $0.00 | |||
| Retained Earnings Accumulated Deficit | -$269.6M | -$11.1M | -$10.7M | -$9.4M | -$9.2M | -$8.8M | -$7.9M | -$6.6M | -$5.2M | -$1.9M | -$1.7M | -$11.3K | ||||
| Liabilities Current | $10.0M | $8.3M | $7.9M | $6.6M | $6.3M | $6.0M | $5.1M | $3.8M | $3.0M | $90.8K | $162.3K | $428.2K | ||||
| Liabilities And Stockholders Equity | $774.0K | $562.5K | $9.1M | $8.9M | $52.1M | $51.3M | $90.1M | $88.2M | $87.0M | $85.8M | $85.5M | $441.9K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$14.1K | -$203.5K | -$240.4K | |||||||||||||
| Assets Current | $85.0K | $14.1K | $2.7K | $35.4K | $43.8K | $65.4K | $35.7K | $54.5K | $673.3K | $1.1M | $1.3M | $16.6K | ||||
| Assets | $774.0K | $562.5K | $9.1M | $8.9M | $52.1M | $51.3M | $90.1M | $88.2M | $87.0M | $85.8M | $85.5M | $441.9K | ||||
| Liabilities | $15.4M | $11.2M | $10.7M | $9.5M | $9.2M | $8.9M | $8.0M | $6.6M | $5.9M | $3.0M | $3.0M | |||||
| Assets Held In Trust Noncurrent | $548.3K | $9.1M | $9.0M | $8.9M | $52.1M | $51.3M | $90.1M | $88.1M | $86.3M | $84.6M | $84.3M | $84.2M | ||||
| Cash | $85.0K | $1.0K | $204.5K | |||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $548.3K | $9.1M | $9.0M | $8.9M | $52.1M | $51.3M | $90.1M | $88.1M | $86.3M | $85.4M | $84.6M | $84.2M | ||||
| Deferred Underwriter Compensation Non Current | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | $2.9M | |||||
| Temporary Equity Accretion To Redemption Value Adjustment | $2.0M | $242.4K | $790.2K | $803.9K | $5.6M | $2.0M | $1.9M | $912.6K | -$380.4K | $16.1M | ||||||
| Accounts Payable And Other Accrued Liabilities Current | $5.1M | $4.8M | $4.6M | $3.9M | $3.8M | $3.8M | $3.7M | |||||||||
| Other Notes Payable Current | $1.4M | $1.4M | $1.4M | $1.3M | $1.3M | $1.1M | $825.0K | |||||||||
| Other Accrued Liabilities Current | $78.2K | $68.4K | $58.6K | $48.6K | $38.6K | $28.8K | $8.9K | |||||||||
| Preferred Stock Value | $1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| Repayments Of Related Party Debt | $80.0K | $160.0K | ||||||||||||||
| Cash And Cash Equivalents At Carrying Value | $85.0K | $1.0K | $204.5K | |||||||||||||
| Common Stock Value | $23.0K | $51.00 | $51.00 | |||||||||||||
| Subsequent Measurement Of Common Stock Subject To Possible Redemption Value | $2.0M | $1.9M | $912.6K | $495.3K | $0.00 | |||||||||||
| Property Plant And Equipment Net | $689.0K | |||||||||||||||
| Other Assets Current | $0.00 | |||||||||||||||
| Accrued Liabilities Current | $1.3M | |||||||||||||||
| Temporary Equity Accretion To Redemption Value | $20.7K | $124.2K | $790.2K | $803.9K | $16.1M | |||||||||||
| Deferred Offering Cost Settled Through Related Party | $0.00 | $203.7K | ||||||||||||||
| Subsequent Measurement Of Common Stock Subject To Possible Redemption | $803.9K | $912.6K | ||||||||||||||
| Accounts Payable And Accrued Liabilities Current | $3.3M | $3.0M | $1.3M | $90.8K | $82.3K | $133.2K | ||||||||||
| Notes Payable Current | $4.5M | $412.5K | ||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$240.4K | $16.6K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$5.9M | -$4.9M | -$632.8K | -$426.1K |
| Net Cash Provided By Used In Financing Activities | $5.9M | $4.9M | -$39.7M | $85.4M |
| Proceeds From Related Party Debt | $5.8M | $4.9M | $842.5K | $25.0K |
| Increase Decrease In Prepaid Expense | $586.0K | $0.00 | -$83.1K | $88.1K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $890.8K | $2.5M | $1.3M | |
| Increase Decrease In Due To Related Parties | $56.5K | $18.0K | ||
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $39.7K | $18.9K | ||
| Net Cash Provided By Used In Investing Activities | $43.4M | $39.7M | -$84.2M | |
| Proceeds From Notes Payable | $842.5K | $80.0K | ||
| Payments For Repurchase Of Common Stock | $43.4M | $40.5M | ||
| Proceeds From Decommissioning Fund | $43.4M | $40.5M | ||
| Payments To Acquire Investments | $825.0K | $84.2M | ||
| Increase Decrease In Accrued Liabilities | $704.0K | -$861.0K | ||
| Proceeds From Issuance Of Private Placement | $5.1M | |||
| Proceeds From Issuance Initial Public Offering | $82.5M | |||
| Payments Of Stock Issuance Costs | $339.1K | |||
| Share Based Compensation | $142.4M | $660.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q3 2023 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$114.1K | -$374.2K | -$240.4K | $0.00 | |
| Net Cash Provided By Used In Financing Activities | $100.0K | $170.7K | $0.00 | $16.6K | |
| Proceeds From Related Party Debt | $100.0K | $170.7K | $412.5K | $25.0K | |
| Increase Decrease In Prepaid Expense | $59.4K | $5.8K | $0.00 | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $132.5K | $53.5K | $1.7M | $0.00 | |
| Increase Decrease In Due To Related Parties | $17.2K | $11.4K | |||
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $9.8K | $9.9K | |||
| Net Cash Provided By Used In Investing Activities | |||||
| Proceeds From Notes Payable | $170.7K | $50.0K | $0.00 | $80.0K | |
| Payments For Repurchase Of Common Stock | |||||
| Proceeds From Decommissioning Fund | |||||
| Payments To Acquire Investments | |||||
| Increase Decrease In Accrued Liabilities | |||||
| Proceeds From Issuance Of Private Placement | |||||
| Proceeds From Issuance Initial Public Offering | |||||
| Payments Of Stock Issuance Costs | $0.00 | $63.4K | |||
| Share Based Compensation |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Diluted EPS * | -$0.78 | -$0.02 | ||
| Preferred Stock Shares Authorized | 45.0M | 45.0M | 1.0M | 1.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 204.8M | 200.0M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 204.8M | 200.0M | ||
| Preferred Stock Shares Outstanding | 5.4M | 0.00 | ||
| Preferred Stock Shares Issued | 5.4M | 0.00 | ||
| Earnings Per Share Basic | $-0.78 | $-0.02 | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Authorized | 740.0M | 200.0M | ||
| Common Stock Shares Outstanding | 230.2M | 200.0M | ||
| Common Stock Shares Issued | 230.2M | 200.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.76 | -$0.01 | -$0.01 | ||||||||||
| Preferred Stock Shares Authorized | 45.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Shares Outstanding Basic | 201.7M | 200.0M | |||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 201.7M | 200.0M | |||||||||||
| Preferred Stock Shares Outstanding | 5.4M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Shares Issued | 5.4M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Earnings Per Share Basic | $-0.76 | $-0.01 | |||||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | |||||||||||
| Common Stock Shares Authorized | 740.0M | ||||||||||||
| Common Stock Shares Outstanding | 229.7M | ||||||||||||
| Common Stock Shares Issued | 229.7M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Investment Income Interest | $1.6M | $3.8M | $1.2M | |
| Operating Costs And Expenses | $1.6M | $3.2M | $1.6M | |
| Prepaid Expense Current | $576.0K | $2.0K | $5.0K | $88.1K |
| Increase In Investment Held In Trust Account Through Issuance Of Promissory Note | $390.3K | $975.0K | ||
| Remeasurement Adjustment On Class A Ordinary Shares Subject To Possible Redemption | 2.0M | 5.6M | ||
| Additional Paid In Capital | $255.0M | $72.6M | ||
| Stock Issued During Period Value New Issues | $54.2M | $25.0K | ||
| Stock Issued1 | $25.0K | |||
| Payment Of Financing And Stock Issuance Costs | $339.1K | |||
| Investment Income Investment Expense | ||||
| Formation Costs And Operating Costs Paid By Related Party | $11.3K | |||
| Formation And Operating Costs | $1.6M | |||
| Reclassification Of Class A Ordinary Shares Subject To Redemption | 72.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment Income Interest | $18.1K | $79.0K | $197.3K | $640.2K | $653.9K | $1.2M | $1.0M | $912.6K | $380.4K | $114.8K | $0.00 | ||
| Operating Costs And Expenses | $374.9K | $246.6K | $213.0K | $168.2K | $368.3K | $505.9K | $563.7K | $1.9M | $73.0K | $145.7K | |||
| Prepaid Expense Current | $0.00 | $14.0K | $21.1K | $42.3K | $64.4K | $22.2K | $45.3K | $93.9K | $132.4K | $151.0K | |||
| Increase In Investment Held In Trust Account Through Issuance Of Promissory Note | $45.2K | $150.0K | |||||||||||
| Remeasurement Adjustment On Class A Ordinary Shares Subject To Possible Redemption | 124.2K | 803.9K | |||||||||||
| Additional Paid In Capital | $255.0M | $0.00 | $0.00 | $0.00 | $0.00 | $24.8K | |||||||
| Stock Issued During Period Value New Issues | $54.2M | $75.0M | $25.0K | ||||||||||
| Stock Issued1 | $0.00 | $25.0K | |||||||||||
| Payment Of Financing And Stock Issuance Costs | |||||||||||||
| Investment Income Investment Expense | $23.1K | $4.4K | |||||||||||
| Formation Costs And Operating Costs Paid By Related Party | $0.00 | $11.3K | |||||||||||
| Formation And Operating Costs | $1.9M | $73.0K | $145.7K | $11.3K | |||||||||
| Reclassification Of Class A Ordinary Shares Subject To Redemption |
Most recent annual filing with the SEC: February 27, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.